Colorectal Cancer Clinical Trial
Official title:
CSP #707D - Colorectal Cancer-Risk Factors for Advanced Disease
Colorectal cancer is the second leading cause of cancer death in the United States each
year. Approximately one million veterans aged 50 and older will develop colorectal cancer
over the remainder of their lives and nearly 433,000 will die from it. Because most cancers
are diagnosed after local or regional spread, nearly half of all patients diagnosed with
colorectal cancer will die. On a national basis, the relative five year survival with
colorectal cancer was estimated at approximately 40% among veterans, substantially lower
than SEER estimates in the general population of 61.7% (colon) and 59.3% (rectum).
Colorectal cancer is preventable through screening, however and, if diagnosed in an early
stage (Dukes' A and B), is curable.
This is the first study to examine factors that might explain the worsened prognosis for
veterans with colorectal cancer. If modifiable factors such as physician and patient delay
in diagnosis, or poverty, explain the increased mortality among veterans, educational
programs and interventions that improve the process of care associated with screening and
diagnosis can be instituted.
Primary Objectives: To identify prognostic factors of late stage disease, particularly those
that are modifiable, that might explain the worsened prognosis with colorectal cancer among
veterans and that also might be responsive to intervention. Interventions directed at these
factors could lead to a decreased mortality among veterans.
Secondary Objectives: To compare outcomes among veterans with similar non-veterans who are
participating in the NCI-funded study: "Population Study of Colon Cancer in Blacks and
Whites" that is in-progress at the University of North Carolina at Chapel Hill.
Primary Outcomes: The primary outcomes are stage of disease and delay of diagnosis. Delay of
diagnosis is determined by length of time between symptom onset and medical consultation
(patient delay) and length of time between first seeking medical consultation and diagnosis
(physician or system delay). Stage of disease will be used as a proxy for survival.
Intervention: N/A
Study Abstract: Colorectal cancer is the second leading cause of cancer death in the United
States each year. Approximately one million veterans aged 50 and older will develop
colorectal cancer over the remainder of their lives and nearly 433,000 will die from it.
Because most cancers are diagnosed after local or regional spread, nearly half of all
patients diagnosed with colorectal cancer will die. On a national basis, the relative five
year survival with colorectal cancer was estimated at approximately 40% among veterans,
substantially lower than SEER estimates in the general population of 61.7% (colon) and 59.3%
(rectum). Colorectal cancer is preventable through screening, however and, if diagnosed in
an early stage (Dukes' A and B), is curable.
This is the first study to examine factors that might explain the worsened prognosis for
veterans with colorectal cancer. If modifiable factors such as physician and patient delay
in diagnosis, or poverty, explain the increased mortality among veterans, educational
programs and interventions that improve the process of care associated with screening and
diagnosis can be instituted.
To-date, 659 subjects have been enrolled. Study participation involves obtaining
demographic, pathology and patient contact data on all colorectal cancer patients at the 14
participating sites and conducting a one-time telephone interview. Preliminary study data
suggests that most veterans with colorectal cancer present with evidence of regional or
distant spread of their colorectal cancer. No significant difference in stage at
presentation among veterans versus the population-based SEER patients is evident. Fewer
veterans present with localized disease (33% versus 40%) and, although not statistically
significant, could suggest a trend toward presentation at a more advanced stage.
Results of this study will provide a profile of patients at high-risk of presenting with
advanced colorectal cancer. This profile may be useful in designing patient and health care
system focused interventions to improve stage at diagnosis.
Final Results: Analyses are underway. A Final Report will be submitted to Durham ERIC within
90 days of study end date (03/31/02).
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |